Isolation of bovine CD34+ bone marrow stem and progenitor cells using a monoclonal antibody against CD34 protein - Archive ouverte HAL Accéder directement au contenu
Poster De Conférence Année : 2023

Isolation of bovine CD34+ bone marrow stem and progenitor cells using a monoclonal antibody against CD34 protein

Pierre Deshuillers

Résumé

Background: There is currently no commercially available bovine anti-CD34 monoclonal antibody. Bovine Hematopoietic Stem and Progenitor Cells (BHSPC) isolation in vitro has had mixed results. Methods: CD34 protein sequences from multiple species were compared in silico to the bovine sequence. A suitable antibody was selected and coupled to R-PhycoErythrin (R-PE). Bone marrow samples from 7 Prim’Holstein calves were collected in EDTA and mononuclear cells were isolated using a density gradient. Antibody binding to BHSPC was monitored by flow cytometry. Labeled BHSPC were separated with anti-PE magnetic beads. Enrichment was evaluated by flow cytometry. Results and discussion: A monoclonal antibody against ovine CD34 was selected based on high homology between bovine and ovine CD34. CD34+ cells accounted for 4.4 to 27.6 % of BHSPC. Variation in CD34+ cells proportion may relate to an individual variation of positive cells in the marrow; however, polymorphism in the coding region of the protein is possible (previously described). Magnetic beads increased CD34+ cells concentration by a 1.96-fold (n = 10, σ = 0.95), but with a weak recovery rate of 1.54 % (n = 8). Conclusions: This experiment describes a new potential commercial anti-CD34 monoclonal antibody for isolation or identification of BHSPC. Although the enrichment may appear low, the increase in cell purity is sufficient for culture and immortalization.
Fichier non déposé

Dates et versions

hal-04380653 , version 1 (08-01-2024)

Identifiants

  • HAL Id : hal-04380653 , version 1

Citer

Quentin Leroy, Delphine Le Roux, Clotilde Rouxel, Anne-Claire Lagrée, Nadia Haddad, et al.. Isolation of bovine CD34+ bone marrow stem and progenitor cells using a monoclonal antibody against CD34 protein. 2023 ACVP/ASVCP Annual Meeting, Oct 2023, Chicago, United States. ⟨hal-04380653⟩
14 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More